VarmX Teams Up with CSL to Develop Novel Coagulation Treatment
VarmX, a biotech company specializing in treatments for patients on direct oral anticoagulants targeting activated factor Xa (FXa DOACs), has entered a strategic collaboration with…
Read More...
Read More...
